MiMedx Group Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.935
- Today's High:
- $8.285
- Open Price:
- $8.16
- 52W Low:
- $2.43
- 52W High:
- $8.6
- Prev. Close:
- $8.16
- Volume:
- 530431
Company Statistics
- Market Cap.:
- $940.48 million
- Book Value:
- -0.109
- Revenue TTM:
- $295.00 million
- Operating Margin TTM:
- -0.43%
- Gross Profit TTM:
- $219.53 million
- Profit Margin:
- -4.28%
- Return on Assets TTM:
- -0.46%
- Return on Equity TTM:
- -15.91%
Company Profile
MiMedx Group Inc had its IPO on 2007-08-22 under the ticker symbol MDXG.
The company operates in the Healthcare sector and Biotechnology industry. MiMedx Group Inc has a staff strength of 867 employees.
Stock update
Shares of MiMedx Group Inc opened at $8.16 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.94 - $8.29, and closed at $7.95.
This is a -2.57% slip from the previous day's closing price.
A total volume of 530,431 shares were traded at the close of the day’s session.
In the last one week, shares of MiMedx Group Inc have increased by +3.52%.
MiMedx Group Inc's Key Ratios
MiMedx Group Inc has a market cap of $940.48 million, indicating a price to book ratio of 82.486 and a price to sales ratio of 1.2984.
In the last 12-months MiMedx Group Inc’s revenue was $295.00 million with a gross profit of $219.53 million and an EBITDA of $2.49 million. The EBITDA ratio measures MiMedx Group Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, MiMedx Group Inc’s operating margin was -0.43% while its return on assets stood at -0.46% with a return of equity of -15.91%.
In Q2, MiMedx Group Inc’s quarterly earnings growth was a positive 400% while revenue growth was a positive 21.5%.
MiMedx Group Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 2.97
Its diluted EPS in the last 12-months stands at $-0.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 2.97. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MiMedx Group Inc’s profitability.
MiMedx Group Inc stock is trading at a EV to sales ratio of 1.6192 and a EV to EBITDA ratio of -22.7781. Its price to sales ratio in the trailing 12-months stood at 1.2984.
MiMedx Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $176.38 million
- Total Liabilities
- $44.46 million
- Operating Cash Flow
- $-348000.00
- Capital Expenditure
- $348000
- Dividend Payout Ratio
- 0%
MiMedx Group Inc ended 2024 with $176.38 million in total assets and $0 in total liabilities. Its intangible assets were valued at $176.38 million while shareholder equity stood at $-12666000.00.
MiMedx Group Inc ended 2024 with $0 in deferred long-term liabilities, $44.46 million in other current liabilities, 116000.00 in common stock, $-195689000.00 in retained earnings and $19.44 million in goodwill. Its cash balance stood at $68.65 million and cash and short-term investments were $68.65 million. The company’s total short-term debt was $0 while long-term debt stood at $48.84 million.
MiMedx Group Inc’s total current assets stands at $141.22 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $48.96 million compared to accounts payable of $8.15 million and inventory worth $16.82 million.
In 2024, MiMedx Group Inc's operating cash flow was $-348000.00 while its capital expenditure stood at $348000.
Comparatively, MiMedx Group Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.95
- 52-Week High
- $8.6
- 52-Week Low
- $2.43
- Analyst Target Price
- $12.06
MiMedx Group Inc stock is currently trading at $7.95 per share. It touched a 52-week high of $8.6 and a 52-week low of $8.6. Analysts tracking the stock have a 12-month average target price of $12.06.
Its 50-day moving average was $7.4 and 200-day moving average was $5.02 The short ratio stood at 3.49 indicating a short percent outstanding of 0%.
Around 489.8% of the company’s stock are held by insiders while 6696.8% are held by institutions.
Frequently Asked Questions About MiMedx Group Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company’s products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.